Lung Cancer Medicare Access to Precise Testing Act
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsors
- 4
- Latest action
- Nov 28, 2025
What it does
The Lung Cancer Medicare Access to Precise Testing Act would amend the Social Security Act to require Medicare coverage for lung cancer biomarker testing starting January 1, 2027, for individuals diagnosed with lung cancer. The bill defines such testing as the analysis of tissue, blood, or bodily fluids to identify specific biomarkers like genes or proteins. It also mandates that Medicare pay 100 percent of the reasonable charges for these tests, ensuring full coverage without cost-sharing for beneficiaries. The legislation affects Medicare recipients with lung cancer and directs the Committees on Energy and Commerce and Ways and Means to review its provisions.
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
Where it goes next
While a bill can still move, the questions are about people and money.